General Information of the Compound
Compound ID
CP0125184
Compound Name
1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea
    Show/Hide
Synonyms
1095173-27-5
2640AH
AKOS027324121
BDBM50385635
CHEMBL2043437
CS-2
EX-A858
GTPL8201
Glasdegib
Glasdegib (PF-04449913)
Glasdegib (USAN/INN)
Glasdegib [USAN:INN]
Glasdegib(PF-04449913)
K673DMO5H9
MolPort-035-789-706
PF 04449913
PF-04449913
PF-04449913;Glasdegib
PF-913
SFNSLLSYNZWZQG-VQIMIIECSA-N
UNII-K673DMO5H9
ZINC68251434
    Show/Hide
Structure
Formula
C21H22N6O
Molecular Weight
374.448
Canonical SMILES
CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N
    Show/Hide
InChI
InChI=1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1
    Show/Hide
InChIKey
SFNSLLSYNZWZQG-VQIMIIECSA-N
CAS
1095173-27-5
Physicochemical Property
logP
3.39158
Rotatable Bonds
3
Heavy Atom Count
28
Polar Areas
96.84
Hydrogen Bond Donor Count
3
Hydrogen Bond Acceptor Count
4
Complexity
28

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 25166913
SID: 57272690
ChEMBL ID
CHEMBL2043437
DrugBank ID
DB11978
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT02397, Protein smoothened
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000387 C3H/10T1/2 clone 8 Mus musculus (Mouse)  1
1
IC50 = 5 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( PF-04449913 )
Drug Name PF-04449913
Company Pfizer
Indication
Chronic myelomonocytic leukaemia
Approved
Solid tumour/cancer
Phase 2
Target(s)
Smoothened homolog (SMO)
Modulator
Serine/threonine-protein kinase mTOR (mTOR)
Inhibitor